Related Experiment Video
Updated: Apr 6, 2026
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
Published on: May 16, 2012
MicroRNA in prostate cancer: Practical aspects
Pallavi A Patil1, Cristina Magi-Galluzzi2
1Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Abstract:
In the last decade, microRNAs (miRNAs) have emerged as biomarkers for cancer diagnosis, prognosis, therapy and prediction of treatment response and have earned a promising role in prostate cancer (PCa) management. A plethora of studies has been conducted on miRNA expression in PCa compared to non-neoplastic prostatic tissue, in PCa of different histologic grades and pathologic stages, in castration resistance prostate cancer (CRPC), in metastatic disease and in response to therapy, with evidence pointing towards distinctive miRNAs differentially expressed in each of these phases. In addition to tissue, miRNA can be detected in blood, serum, and urine. The aim of this review is to survey studies conducted on human prostate tissue and biofluids and to consolidate trustworthy data on the role of miRNA in the occurrence and progression of PCa, with a delineation of differentially expressed miRNAs and an analysis of their association with PCa prognosis, progression to CRPC and metastatic disease, as well as their correlation with response to chemotherapy and hormonal therapy. Changes in circulating miRNAs may represent potentially useful non-invasive biomarkers for PCa diagnosis, staging and prediction of outcome.
Insights
MicroRNAs (miRNAs) are emerging as key biomarkers in prostate cancer (PCa) management. This review consolidates data on their role in PCa diagnosis, progression, and treatment response, highlighting their potential as non-invasive biomarkers.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- MicroRNAs (miRNAs) have become significant biomarkers for cancer management over the past decade.
- Their role in prostate cancer (PCa) spans diagnosis, prognosis, therapy, and treatment response prediction.
- Distinct miRNA expression patterns are observed across various PCa stages, including castration-resistant (CRPC) and metastatic disease.
Purpose of the Study:
- To review studies on miRNA expression in human prostate tissue and biofluids.
- To consolidate reliable data on miRNA involvement in PCa occurrence and progression.
- To analyze differentially expressed miRNAs and their association with PCa prognosis, CRPC, metastasis, and treatment response.
Main Methods:
- Literature review of studies on miRNA expression in prostate cancer.
- Analysis of miRNA detection in both tissue and biofluids (blood, serum, urine).
- Delineation of differentially expressed miRNAs and their correlation with clinical outcomes.
Main Results:
- Numerous studies show distinct miRNA expression profiles in PCa compared to normal tissue.
- Specific miRNAs are differentially expressed across different PCa grades, stages, and resistance statuses (CRPC).
- Circulating miRNAs in biofluids show potential as non-invasive biomarkers for PCa diagnosis and outcome prediction.
Conclusions:
- MicroRNAs play a crucial role in prostate cancer progression and management.
- Differentially expressed miRNAs are associated with PCa prognosis, metastasis, and treatment response.
- Circulating miRNAs offer promising avenues for non-invasive PCa diagnosis, staging, and outcome prediction.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs